title: Cost-of-illness study in acromegalic patients in Italy.
abstract: BACKGROUND
  acromegalic therapeutic goals are directed at removing the tumor, preventing tumor re-growth and reducing long-term morbidity and mortality. In this scenario, the acromegalic patient needs a variety of health resources (diagnostic tests, surgery, radiotherapy, specialist visits and drugs) for his/her cure, in order to decrease/stop the progression of the disease and to cure the co-morbid diseases. Lack of epidemiological data has suggested performing an Italian retrospective study aiming to assess the health resource consumption that is caused by acromegalic cure and the relative co-morbidities, in order to estimate the amount of the direct costs of acromegalic patients.
  
  
  METHODS
  a retrospective study was performed on a total of 134 patients (142 patients selected, 76 in Genoa and 66 in Turin) for a period of about 7 yr preceding the enrolment date. Only direct costs were evaluated by performing an analysis on the perspective of Italian Healthcare Service (SSN).
  
  
  RESULTS
  the mean total direct costs for acromegaly cure ranged from 7,968.41 to 12,533.02 Euros/yr (p < 0.01; Mann Whitney Test), respectively, for Responders and Non-Responders. The cost driver was drug (SS analogs) for acromegalic cure. The co-morbidity conditions associated to acromegalic Non-Responder patients are clearly higher than those with well-controlled disease.
  
  
  CONCLUSIONS
  the study supports the hypothesis that controlled patients drove a saving for SSN in comparison to poor control patients that use more health resources.
authors.affiliation: Outcome Research Unit, NRHCO Department, Pfizer Italia, Rome. guido.didoni@pfizer.com
authors.forename: G
authors.initials: G
authors.lastname: Didoni
authors.forename: S
authors.initials: S
authors.lastname: Grottol
authors.forename: V
authors.initials: V
authors.lastname: Gasco
authors.forename: M
authors.initials: M
authors.lastname: Battistini
authors.forename: D
authors.initials: D
authors.lastname: Ferone
authors.forename: M
authors.initials: M
authors.lastname: Giusti
authors.forename: F
authors.initials: F
authors.lastname: Ragazzoni
authors.forename: P
authors.initials: P
authors.lastname: Ruffo
authors.forename: E
authors.initials: E
authors.lastname: Ghigo
authors.forename: F
authors.initials: F
authors.lastname: Minuto
mesh_terms: D000172:Acromegaly / Q000191:economics* / Q000628:therapy*; D015331:Cohort Studies; D015897:Comorbidity; D017046:Cost Savings; D017281:Cost of Illness; D003365:Costs and Cost Analysis; D005260:Female; D017048:Health Care Costs / Q000706:statistics & numerical data; D006296:Health Services / Q000191:economics* / Q000706:statistics & numerical data*; D006801:Humans; D007558:Italy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies